ArticleClinical ophthalmology (Auckland, N.Z.)2013
Emerging roles for antiangiogenesis factors in management of ocular disease.
Article in Clinical ophthalmology (Auckland, N.Z.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Genotypes of SNPs of key genes regulate susceptibility and drug sensitivity to neovascular AMD in the human population.BMJ open ophthalmology · 2025Article
- A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- The Question of a Role for Statins in Age-Related Macular Degeneration.International journal of molecular sciences · 2018Review
- Vertebrate embryos as tools for anti-angiogenic drug screening and function.Reproductive toxicology (Elmsford, N.Y.) · 2017Review
- Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.Scientific reports · 2016Article
- Article
- Current perspectives on ranibizumab.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
- Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis.Clinical, cosmetic and investigational dermatology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first antivascular endothelial growth factor (anti-VEGF) was developed as an anticancer drug for colonic carcinomas. Since then, anti-VEGFs have developed in scope and indications. They have revolutionized the treatment of exudative macular degeneration and have had a major impact on treatment of several other conditions. This has resulted in an increased number of patients seeking treatment with new treatment options and has had a considerable financial impact on health care resources. Anti-VEGFs have been used in the treatment of all age groups of the population ranging from infants where it is used for treatment of retinopathy of prematurity to the elderly where it is used in exudative macular eegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.